Comprehensive online regulatory training aligned with the European Medicines Agency (EMA), EU GMP, and ICH standards — trusted by EU pharmaceutical professionals, sponsors, and CROs. Self-paced. 21 CFR Part 11 compliant certificates. Inspection-ready training records for EU regulatory audits.
The European Union has a highly structured regulatory framework for pharmaceuticals and biologics, centralised under the European Medicines Agency (EMA) and the national competent authorities of member states. The framework is based on Directive 2001/83/EC and Regulation (EC) No 726/2004. EU regulatory professionals must master the requirements for the Centralised Procedure, Marketing Authorisation Applications (MAAs), and the unique requirements of the EU clinical trial landscape (EU-CTR), all while adhering to ICH guidelines for global submissions.
| Agency/Standard | Framework | Application |
|---|---|---|
| EMA | Regulation (EC) No 726/2004 | Centralised procedure for marketing authorisation |
| EMA | Directive 2001/83/EC | Community code for medicinal products for human use |
| EMA | EU GMP (EudraLex Volume 4) | Good Manufacturing Practice for medicinal products |
| EU | EU Clinical Trials Regulation (EU-CTR) | Unified system for clinical trial authorisation & supervision |
| ICH | ICH Guidelines (E, M, Q, S series) | International harmonisation for global drug development |
All courses are self-paced, available online, and include 21 CFR Part 11 compliant certificates with verifiable IDs — accepted as documented training records during regulatory inspections.
Comprehensive certification covering the global pharmaceutical regulatory landscape. This program provides an end-to-end understanding of the drug development lifecycle with a strong emphasis on the European regulatory environment, including the structure and requirements of the EMA, the Centralised Procedure, and national level submissions. The curriculum is structured to provide foundational regulatory knowledge and advanced strategic capabilities across all major application types.
This program covers the entire drug development and approval process. While focused on the US NDA, the knowledge of the CTD (Common Technical Document) format and the structure of submission dossiers is directly transferable to preparing Marketing Authorisation Applications (MAAs) for the EMA. Understanding the FDA's approach also provides a comparative perspective crucial for global regulatory strategy.
Enroll in Mastering the NDAProvides a comprehensive understanding of the IND framework in the US. This is essential for EU professionals working on global clinical development programs, as understanding the FDA's requirements for clinical trial authorization and safety reporting is vital for parallel submissions and global trial conduct.
Enroll in The (IND) FrameworkProvides comprehensive knowledge of BLA submissions to the FDA. This training is critical for EU biotech companies and professionals seeking to enter the US market or understand the global regulatory landscape for biological products. The principles of CMC, nonclinical, and clinical data requirements are globally applicable.
Enroll in Biologics License ApplicationCovers the entire orphan drug development process, including the US Orphan Drug Act. This is highly relevant for EU companies developing treatments for rare diseases, as they often seek orphan designation from both the EMA and the FDA. The course covers the strategic benefits of orphan drug designation.
Enroll in Mastering the Orphan Drug NDAProvides an in-depth understanding of the regulatory requirements for preparing and submitting ANDAs to the FDA. This is vital for EU-based generic pharmaceutical companies looking to export to the U.S. market.
Enroll in ANDA ComplianceRegulatory training is a critical requirement for all personnel involved in the research, development, and submission of medicinal products within the European Union. Mastering the complexities of the European Medicines Agency (EMA), national competent authorities, and ICH guidelines is essential for successful market access and compliance.
The European Medicines Agency (EMA) coordinates GMP, GCP, and pharmacovigilance inspections through its network of national competent authorities. Additionally, individual EU member states conduct their own regulatory inspections. Inadequate training can lead to serious findings that impact your organization's ability to operate and market products in the EU.
Common inspection observations related to regulatory and quality training include:
Our 21 CFR Part 11 compliant certificates provide auditable, documented training records that FDA investigators accept during inspections.
The EU is a founding member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), the international body that harmonises GMP and regulatory standards across over 55 member countries. This has direct implications for how regulatory affairs professionals structure submissions and maintain compliance.
PIC/S membership means that regulatory frameworks, including EU GMP and ICH guidelines, are aligned with international expectations. Training that covers PIC/S-harmonised principles is essential for EU professionals preparing submissions for global markets.
Marketing Authorisations and regulatory dossiers prepared in alignment with EMA standards and PIC/S principles are recognised by many international regulators. Our training covers the core regulatory requirements recognised by all PIC/S member authorities — including FDA, Health Canada, and WHO.
EU companies supplying the US, Canada, or other markets must navigate multiple regulatory frameworks simultaneously. Our regulatory affairs courses cover all relevant frameworks in a single, comprehensive program, helping you prepare submissions that meet the requirements of the EMA, FDA, and other major regulators.
Train your entire QA, warehouse, or logistics team with our group enrollment options for EU pharmaceutical companies. Get a custom quote in 24 hours.
| Feature | GxP Trainings |
|---|---|
| FDA 21 CFR Part 205 aligned | |
| FDA 21 CFR Parts 210 & 211 aligned | |
| DSCSA requirements covered | |
| EMA Centralised Procedure aligned | |
| WHO GDP aligned | |
| ICH Q9 (Quality Risk Management) covered | |
| 21 CFR Part 11 compliant certificate | |
| Self paced — study on your schedule | |
| Instant certificate download | |
| Verifiable certificate ID | |
| Group / corporate enrollment |
Yes. The EMA and national competent authorities do not mandate a specific training provider. They expect documented, role-appropriate training. Our 21 CFR Part 11 compliant certificates provide verifiable proof of training that is accepted during GCP and GMP inspections.
While the course focus is on the FDA framework, the general principles of clinical trial conduct and the IND structure provide a robust foundation for understanding the stringent requirements of the EU-CTR. Our GCP training specifically covers the EU CTR for clinical operations professionals.
Yes. We offer corporate and group enrollment options for teams of all sizes. Contact us for a custom quote.
All courses include lifetime access — study at your own pace, on your own schedule.
Yes. Each certificate includes a unique verifiable ID that can be checked at gxptrainings.com/verify-certificate/
Equip yourself and your team with the Regulatory Affairs knowledge and documented training records required for EMA, EU GMP, and WHO inspection readiness.